The use of medical cannabis as a possible treatment for ASD has caught the attention of researchers worldwide, with Israel leading in global medical cannabis research. The endocannabinoid system of the body is a regulatory feedback system which influences the function of many other systems – neurotransmitters, hormones and more. This means that it tells the body to send more or less of these other chemicals to where they are needed. The endocannabinoid system sends its messages via cannabinoids that are produced’ in house’ (CB1 and CB2) and there are receptors for these cannabinoids on almost all parts of the body. When the endocannabinoid system isn’t working right, the body isn’t getting the information it needs to know how much and where to send various other chemicals and imbalances can then occur.
In the case of ASD, it has been seen that individuals with ASD often may lack certain cannabinoids normally found in the human body (Lower circulating endocannabinoid levels in children with autism spectrum disorder). The theory of treatment with medical cannabis is to give the body the plant-based version of the cannabinoids that are lacking and to restore balance to the endocannabinoid system and thus to the various systems under its influence. In studies performed in Israel treating children with ASD with medical cannabis, significant improvement was observed in many of the core issues of ASD including speech, social interaction, challenging behaviors and more. (Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems—A Retrospective Feasibility Study and
Autism Spectrum Disorder and Medical Cannabis: Review and Clinical Experience)
It also is known that cannabis is a strong anti-inflammatory and can have significant immune-modulating effects in the body (Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities). We at Cell-El, Ltd are very interested in exploring potential improvements in speech, social interaction abilities and other behavioral changes through treatment with medical cannabis, and potential correlations with possible changes in immune system biomarkers. We hope to have the opportunity to evaluate more closely by possibly testing biomarkers of children with ASD pre and post treatment with medical cannabis. We would thus obtain more objective data and understanding of what the cannabis is actually changing in the child with ASD on a biological level.
Help Us Help You
Better diagnostics for ASD based on laboratory-measured objective biomarkers can possibly enable researchers and clinicians to provide more precise and personalized treatment. You too can make a difference in the lives of children with ASD and their families by joining the Cell-El study. Cell-El is recruiting for two of our study cohorts. We are recruiting mothers, and their infants aged 10-19 months who have not been diagnosed with ASD but who have a sibling diagnosed with ASD. Cell-El is also recruiting children diagnosed with ASD between the ages of 2-18 years old whose parents are planning to take them privately to a clinic offering Stem Cell treatment for ASD.
Please contact Leah at [email protected] or fill out the form to find out about eligibility to participate in our diagnostic study and please help spread the word about the Cell-El study. Sharing our study will enable our important biomarker diagnostic tool to be integrated into autism treatment as quickly as possible.